Merck & Co., Inc. - Jan 31, 2025 Form SCHEDULE 13G/A Schedule Report for Evaxion Biotech A/S (EVAX)

Filing Manager
Merck & Co., Inc.
Reporting Manager
Merck & Co., Inc.
Security
Evaxion Biotech A/S American Depositary Shares, each representing fifty Ordinary Shares, DKK 0.25 nominal value per share
Symbol
EVAX
Shares outstanding
316M shares
Disclosed Ownership
63M shares
Ownership
20%
Form type
SCHEDULE 13G/A
Date filed
2/3/2025, 04:15 PM
Date of event
Jan 31, 2025
SEC
View on sec.gov

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Merck & Co., Inc. 19.96% 63M 0 63M /s/ Kelly Grez Kelly Grez/Corporate Secretary
Merck Sharp & Dohme LLC 19.96% 63M 0 63M /s/ Jon Filderman Jon Filderman/Vice President
Merck Global Health Innovation Fund, LLC 19.96% 63M 0 63M /s/ William Taranto William Taranto/President & General Partner